Process Development and Manufacturing of Therapeutic Antibodies

Handbook of Therapeutic Antibodies: Second Edition

Volumn 2-4, Issue , 2014, Pages 601-664

  Jacobi, Alexander ^a   Enenkel, Barbara ^a   Garidel, Patrick ^a   Eckermann, Christian ^a   Knappenberger, Mathias ^a   Presser, Ingo ^a   Kaufmann, Hitto ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Analytical methods; Antibody; Cell culture; High throughput; Manufacturing; Process development

Indexed keywords

CELL CULTURE; MANUFACTURE;

ANALYTICAL METHOD; HIGH THROUGHPUT; PROCESS DEVELOPMENT; THERAPEUTIC ANTIBODIES;

ANTIBODIES;

EID: 84961291539     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527682423.ch22     Document Type: Chapter

References (159)

1. Baumeister, H., Goletz, S. (2010) A Matter of Cell Line Development. European BioPharmaceutical Review (Apr. 2010).
2. Jostock, T. (2011) Expression of antibody in mammalian cells, in Antibody Expression and Production, Cell Engineering, vol. 7, Chapter 1 (ed. M. Al-Rubeai), Springer Science+Business Media B.V.
3. Fan, L., Kadura, I., Krebs, L.E., Hatfield, C.C., Shaw, M.M., and Fraye, C.C. (2012) Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells. Biotechnol. Bioeng., 109 (4), 1007-1015.
4. Berlec, A. and Strukelj, B. (2013) Current stage and recent advances in biopharmaceutical production in Escherichia coli, yeast and mammalian cells. J. Ind. Microbiol. Biotechnol., 40, 257-274.
5. Lai, T., Yang, Y., and Ng, S.K. (2013) Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals, 6, 579-603.
6. Kennard, M.L., Goosney, D.L., Monteith, D., Roe, S., Fischer, D., and Mott, J. (2009) Auditioning of CHO host cell lines using the artificial chromosome expression (ACE) technology. Biotechnol. Bioeng., 104 (3), 526-539.
7. Becker, E., Florin, L., Pfizenmaier, K., and Kaufmann, H. (2008) An XBP-1 dependent bottle-neck in production of IgG subtype antibodies in chemically defined serum-free Chinese hamster ovary (CHO) fed-batch processes. J. Biotechnol., 135 (2), 217-223.
8. Becker, E., Florin, L., Pfizenmaier, K., and Kaufmann, H. (2010) Evaluation of a combinatorial cell engineering approach to overcome apoptotic effects in XBP-1(s) expressing cells. J. Biotechnol., 146 (4), 198-206.
9. Florin, L., Pegel, A., Becker, E., Hausser, A., Olayioye, M.A., and Kaufmann, H. (2009) Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells. J. Biotechnol., 141 (1-2), 84-90.
10. Raju, T.S. (2008) Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol., 20, 471-478.
11. Beck, A., Cochet, O., and Wurch, T. (2010) GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. Expert Opin. Drug Discovery, 5 (1), 95-111.
12. Sheeley, D.M., Merrill, B.M., and Taylor, L.C. (1997) Characterization of monoclonal antibody glycosylation:comparison of expression systems and identification of terminal a-linked galactose. Anal. Biochem., 247, 102-110.
13. Urlaub, G. and Chasin, L.A. (1980) Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. USA., 77 (7), 4216-4220.
14. Von Horsten, H.H., Ogorek, C., Blanchard, V., Demmler, C., Giese, C., Winkler, K., Kaup, M., Berger, M., Jordan, I., and Sandig, V. (2010) Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. Glycobiology, 20 (12), 1607-1618.
15. Damasceno, L.M., Huang, C.-J., and Batt, C.A. (2012) Protein secretion in Pichia pastoris and advances in protein production. Appl. Microbiol. Biotechnol., 93, 31-39.
16. Hamilton, S.R., Davidson, R.C., Sethuraman, N., Nett, J.H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T.A., Li, H., Choi, B.-K., Hopkins, D., Wischnewski, H., Roser, J., Mitchell, T., Strawbridge, R.R., Hoopes, J., Wildt, S., and Gerngross, T.U. (2006) Humanization of yeast to produce complex terminally sialylated glycoproteins. Science, 313 (5792), 1441-1443.
17. Zhang, N., Liu, L., Dumitru, C.D., Cummings, N.R.H., Cukan, M., Jian, Y., Li, Y., Li, F., Mitchell, T., Mallem, M.R., Ou, Y., Patel, R.N., Vo, K., Wang, H., Burnina, I., Choi, B.-K., Huber, H., Stadheim, T.A., and Zha, D. (2011) Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs, 3 (3), 289-298.
18. Ha, S., Wang, Y., and Rustandi, R.R. (2011) Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris. MAbs, 3 (5), 453-460.
19. Fischer, R., Stoger, E., Schillberg, S., Christon, P., and Twyman, R.M. (2004) Plant-based production of biopharmaceuticals. Curr. Opin. Plant Biol., 7, 152-158.
20. Durocher, Y. and Butler, M. (2009) Expression systems for therapeutic glycoprotein production. Curr. Opin. Biotechnol., 20, 700-707.
21. Rasala, B.A., Muto, M., Lee, P.A., Jager, M., Cardoso, R.M.F., Behnke, C.A., Kirk, P., Hokanson, C.A., Crea, R., Mendez, M., and Mayfield, S.P. (2010) Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii. Plant Biotechnol. J., 8, 719-733.
22. Waegeman, H. and Soetaert, W. (2011) Increasing recombinant protein production in Escherichia coli through metabolic and genetic engineering. J. Ind. Microbiol. Biotechnol., 38, 1891-1910.
23. Reilly, D.E. and Yansura, D.G. (2010) Production of monoclonal antibodies in E. coli, in Current Trends in Monoclonal Antibody Development and Manufacturing, Biotechnology: Pharmaceutical Aspects (eds S.J. Shire et al.), American Association of Pharmaceutical Scientists. doi: 10.1007(978-0-387-76643-0 17
24. Jackman, J., Chen, Y., Huang, A., Moffat, B., Scheer, J.M., Leong, S.R., Lee, W.P., Zhang, J., Sharma, N., Lu, Y., Iyer, S., Shields, R.L., Chiang, N., Bauer, M.C., Wadley, D., Roose-Girma, M., Vandlen, R., Yansura, D.G., Wu, Y., and Wu, L.C. (2010) Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J. Biol. Chem., 285 (27), 20850-20859.
25. Pandhal, J. and Wright, P.C. (2010) N-linked glycoengineering for human therapeutic proteins in bacteria. Biotechnol. Lett., 32, 1189-1198.
26. Allison, D.W., Aboytes, K.A., Fong, D.K., Leugers, S.L., Johnson, T.K., Loke, H.N., and Donahue, L.M. (2005) Development and optimization of cell culture media-genomic and proteomic approaches. Bioprocess Int., 3, 2-7.
27. Hewlett, G. (1991) Strategies for optimising serum-free media. Cytotechnology, 5 (1), 3-14.
28. Kempken, R., Howladt, M., and Walz, F. (2006) Kultur von Tierzellen, in Bioprozeßtechnik (ed. H. Chmiel), Elsevier GmbH, München.
29. Rouiller, Y., Périlleux, A., Collet, N., Jordan, M., Stettler, M., Broly, H. (2013) A high-throughput media design approach for high performance mammalian fed-batch cultures. MAbs, 5 (3), Epub ahead of print.
30. Schaub, J., Clemens, C., Schorn, P., Hildebrandt, T., Rust, W., Mennerich, D., Kaufmann, H., and Schulz, T.W. (2010) CHO gene expression profiling in biopharmaceutical process analysis and design. Biotechnol. Bioeng., 105 (2), 431-438.
31. Murakami, S., Chiou, T.W., and Wang, D.I. (1991) A fiber-bed bioreactor for anchorage-dependent animal cell cultures: part II. Scaleup potential. Biotechnol. Bioeng., 37 (8), 762-769.
32. Preissmann, A., Wiesmann, R., Buchholz, R., Werner, R.G., Noé, W. (1997) Investigations on oxygen limitations of adherent cells growing on macroporous microcarriers. Cytotechnology, 24 (2), 121-134.
33. Singh, V. (1999) Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology, 30 (1-3), 149-158.
34. Shukla, A.A. and Gottschalk, U. (2013) Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol., 31 (3), 147-154.
35. Storhas, W. (1994) Bioreaktoren und periphere Einrichtungen, Springer Verlag, Berlin, pp. 279-297.
36. Mulukutla, B.C., Kahn, S., Lange, A., and Hu, W.-S. (2010) Glucose metabolism in mammalian cell culture:new insights for tweaking vintage pathways. Trends Biotechnol., 28, 476-484.
37. Lu, F., Toh, P.C., Burnett, I., Li, F., Hudson, T., Amanullah, A., and Li, J. (2013) Automated dynamic fed-batch process and media optimization for high productivity cell culture process development. Biotechnol. Bioeng., 110 (1), 191-205.
38. Kim, J.Y., Kim, Y.G., and Lee, G.M. (2012) CHO cells in biotechnology for production of recombinant proteins:current state and further potential. Appl. Microbiol. Biotechnol., 93 (3), 917-930.
39. Borys, M.C., Linzer, D.I., and Papoutsakis, E.T. (1993) Culture pH affects expression rates and glycosylation of recombinant mouse placental lactogen proteins by Chinese hamster ovary (CHO) cells. Biotechnology (New York), 11 (6), 720-724.
40. Sandadi, S., Ensari, S., and Kearns, B. (2005) Heuristic optimization of antibody production by Chinese hamster ovary cells. Biotechnol. Prog., 21, 1537-1542.
41. Kaufmann, H., Mazur, X., Fussenegger, M., and Bailey, J.E. (1999) Influence of low temperature on productivity, proteome and protein phosphorylation of CHO cells. Biotechnol. Bioeng., 63 (5), 573-582.
42. Trummer, E., Fauland, K., Seidinger, S., Schriebl, K., Lattenmayer, C., Kunert, R., Vorauer-Uhl, K., Weik, R., Borth, N., Katinger, H., and Müller, D. (2006) Process parameter shifting:part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol. Bioeng., 94 (6), 1033-1044.
43. Kunkel, J.P., Jan, D.C., Jamieson, J.C., and Butler, M. (1998) Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J. Biotechnol., 62 (1), 55-71.
44. Li, F., Vijayasankaran, N., Shen, A.Y., Kiss, R., and Amanullah, A. (2010) Cell culture processes for monoclonal antibody production. MAbs, 2 (5), 466-477.
45. Pohlscheidt, M., Jacobs, M., Wolf, S., Thiele, J., Jockwer, A., Gabelsberger, J., Jenzsch, M., Tebbe, H., Burg, J., (2013) Optimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactors. Biotechnol., Prog. 29 (1), 222-229.
46. Sung, Y.H., Song, Y.J., Lim, S.W., Chung, J.Y., and Lee, G.M. (2004) Effect of sodium butyrate on the production, heterogeneity and biological activity of human thrombopoietin by recombinant Chinese hamster ovary cells. J. Biotechnol., 112 (3), 323-335.
47. Eriksson, L., Johansson, E., Kettaneh-Wold, N., Wikström, C., and Wold, S. (2000) Design of Experiments:Principles and Applications, Umetrics Academy Book, Umêa.
48. Huang, Y.M., Hu, W., Rustandi, E., Chang, K., Yusuf-Makagiansar, H., and Ryll, T. (2010) Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog., 26 (5), 1400-1410.
49. Werner, R.G. (2005) The development and production of biopharmaceuticals:technological and economic success factors. BioProcess International (Sept. 2005), pp. 6-15.
50. Nagle, P.C., Nicita, C.A., Gerdes, L.A., and Schmeichel, C.J. (2008) Characteristics of and trends in the late-stage biopharmaceutical pipeline. Am. J. Manag. Care, 14 (4), 226-229.
51. Reichert, J.M. and Dhimolea, E. (2012) The future of antibodies as cancer drugs. Drug Discovery Today, 17 (17-18), 954-963.
52. Reichert, J.M. (2012) Marketed therapeutic antibodies compendium. MAbs, 4 (3), 413-415.
53. Li, R., Dowd, V., Stewart, D.J., Burton, S.J., and Lowe, C.R. (1998) Design, synthesis, and application of a protein A mimetic. Nat. Biotechnol., 16, 190-195.
54. Follman, D. and Fahrner, R.L. (2004) Factorial screening of antibody purification processes using three chromatography steps without protein A. J. Chromatogr. A, 1024, 79-85.
55. El Khoury, G., Rowe, L.A., and Lowe, C.R. (2012) Biomimetic affinity ligands for immunoglobulins based on the multicomponent Ugi reaction. Methods Mol. Biol., 800, 57-74.
56. Roque, A.C., Gupta, G., and Lowe, C.R. (2005) Design, synthesis, and screening of biomimetic ligands for affinity chromatography. Methods Mol. Biol., 310, 43-62.
57. Jacobi, A., Eckermann, C., and Ambrosius, D. (2007) Developing and antibody purification process, in Bioseparation and Bioprocessing (ed. G. Subramanian), Wiley-VCH Verlag GmbH, Weinheim, pp. 431-457.
58. Bergemann, K., Eckermann, C., Garidel, P., Grammatikos, S., Jacobi, A., Kaufmann, H., Kempken, R., and Pisch-Heberle, S. (2007) in Handbook of Therapeutic Antibodies (ed. S. Dübel), Wiley-VCH Verlag GmbH, Weinheim, pp. 199-237.
59. Creighton, T.E. (1996) Proteins: Structures and Molecular Properties, 2nd edn, Freeman & Company, New York.
60. Walter, J.K. (1998) in Bioseparation and Bioprocessing (ed. G. Subramanian), Wiley-VCH Verlag GmbH, Weinheim, pp. 447-460.
61. Nagorsen, D., Kufer, P., Baeuerle, P.A., and Bargou, R. (2012) Blinatumomab:a historical perspective. Pharmacol. Ther., 136 (3), 334-342.
62. Mant, C.T. and Hodges, R.S. (2008) Mixed-mode hydrophilic interaction/cation-exchange chromatography (HILIC/CEX) of peptides and proteins. J. Sep. Sci., 31, 2754-2773.
63. Snyder, M.A. (2011) Working with a powerful and robust mixed-mode resin for protein purification. BioProcess International, pp. 50-53.
64. Cheong, W.J., Yang, S.H., and Ali, F. (2013) Molecular imprinted polymers for separation science: a review of reviews. J. Sep. Sci., 36, 609-628.
65. Longqin, L., Tianwei, T., and Frantisek, S. (2013) Molecular imprinting of proteins in polymers attached to the surface of nanomaterials for selective recognition of biomacromolecules. Biotechnol. Adv., 13 (8), 1172-1186.
66. Gagnon, P., Rodriquez, G., and Zaidi, S. (2011) Dissociation and fractionation of heavy and light chains from IgG monoclonal antibodies. J. Chromatogr. A, 1218, 2402-2404.
67. Nischang, I. (2013) Porous polymer monoliths: morphology, porous properties, polymer nanoscale gel structure and their impact on chromatographic performance. J. Chromatogr. A, 1287, 39-58.
68. Branovic, K., Buchacher, A., Barut, M., Strancar, A., and Josic, D. (2003) Application of semi-industrial monolithic columns for downstream processing of clotting factor IX. J. Chromatogr. B, 790, 175-182.
69. Wolff, M.W. and Udo Reichl, U. (2011) Downstream processing of cell culturederived virus particles. Expert Rev. Vaccines, 10 (10), 1451-1475.
70. Nicoud, R.M. (1998) in Bioseparation and Bioprocessing (ed. G. Subramanian), Wiley-VCH Verlag GmbH, Weinheim, pp. 475-508.
71. Holzer, M., Osuna-Sanchez, H., David, L. (2008) Multicolumn chromatography:A new approach to relieving capacity bottlenecks for downstream processing efficiency. BioProcess International, September, 74-82.
72. Demirci, A., Leu, F., and Bailey, F.J. (2012) Comparison of radial and axial flow chromatography for monoclonal antibody downstream processing at bench and pilot scales. Am. J. Biochem. Biotechnol., 8 (4), 255-262.
73. Ruiz-Ruiz, F., Benavides, J., Aguilar, O., and Rito-Palomares, M. (2012) Aqueous two-phase affinity partitioning systems: current applications and trends. J. Chromatogr. A, 1244, 1-13.
74. Tebbey, P.W. and Rink, C. (2009) Target product profile: a renaissance for its definition and use. J. Med. Market., 9, 301-307.
75. LeHir, A. (2001) Pharmacie galénique, Edition Masson, Paris.
76. Langguth, P., Fricker, G., and Wunderli-Allenspach, H. (2004) Biopharmazie, Wiley-VCH Verlag GmbH, Weinheim.
77. Garidel, P. and Bassarab, S. (2008) in Quality for Biologics: Critical Quality Attributes, Process and Change Control, Production Variation, Characterisation, Impurities and Regulatory Concerns (ed. N. Lyscon), Chapter 7, Biopharm Knowledge Publishing, pp. 94-113.
78. Narhi, L.O. (ed.) (2013) Biophysics for Therapeutic Protein Development, Springer, New York, Heidelberg.
79. Mahler, H.C., Borchard, G., and Luessen, H.L. (eds) (2010) Protein Pharmaceuticals, Editio Cantor Verlag, Aulendorf.
80. Samra, H.S. and He, F. (2012) Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies. Mol. Pharmaceutics, 9, 696-707.
81. Garidel, P. (2012) Right angle light scattering protein thermostability screening: from research to development. Spectrosc. Eur., 24 (1), 13-18.
82. Liu, J., Nguyen, M.D.H., Andya, J.D., and Shire, S.J. (2005) Reversible selfassociation increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J. Pharm. Sci., 94, 1928-1940.
83. Rouessac, F., Rouessac, A. (2004) Analyses chimique. Méthodes et techniques instrumentals modernes. Edition Dunod, Paris.
84. Kellner, R., Mermet, J.M., Otto, M., Valcárcel, M., and Widmer, H.M. (2004) Analytical Chemistry, Wiley-VCH Verlag GmbH, Weinheim.
85. Garidel, P. and Schott, H. (2006) Fourier-transform midinfrared spectroscopy for the analysis and screening of liquid protein formulations. Part 2: detailed analysis and applications. Bioprocess Int., 4 (6), 48-55.
86. Wang, W. and Roberts, C.J. (eds) (2010) Aggregation of Therapeutic Proteins, John Wiley & Sons, Inc., Hoboken, NJ.
87. Tatford, O.C., Gomme, P.T., and Bertolini, J. (2004) Analytical techniques for the evaluation of liquid protein therapeutics. Biotechnol. Appl. Biochem., 40, 67-81.
88. Sine, J.P. (2003) Séparation et analyse des biomolécules, Edition Ellipses, Paris.
89. Fraunhofer, W. and Winter, G. (2004) The use of asymmetrical flow fieldflow fractionation in pharmaceutics and biopharmaceutics. Eur. J. Pharm. Biopharm., 58, 369-383.
90. Hollas, J.M. (2003) Spectroscopie, Edition Dunod, Paris.
91. Manning, M.C. (2005) Use of infrared spectroscopy to monitor protein structure and stability. Expert Rev. Proteomics, 2, 731-743.
92. Schüle, S., Schultz-Fademrecht, T., Bassarab, S., Bechtold-Peters, K., Frieß, W., and Garidel, P. (2004) Determination of the secondary protein structure of IgG1 antibody formulations for spray drying. Respir. Drug Delivery, 2, 377-380.
93. Schüle, S., Schultz-Fademrecht, T., Bassarab, S., Bechtold-Peters, K., Frieß, W., and Garidel, P. (2005) Spray drying of IgG1 antibody formulations: a CD and FTIR investigation with respect to protein secondary structure. Respir. Drug Delivery, 1, 185-188.
94. Arakawa, T. and Timasheff, S.N. (1985) Theory of protein solubility. Methods Enzymol., 114, 49-77.
95. Middaugh, C.R., Tisel, W.A., Haire, R.N., and Rosenberg, A. (1979) Determination of the apparent thermodynamic activities of saturated protein solutions. J. Biol. Chem., 254, 367-370.
96. Capelle, M.A.H. and Arvinte, T. (2008) High throughput formulation screening of therapeutic proteins. Drug Discovery Today: Technol., 5 (2-3), e71-e79.
97. Capelle, M.A.H., Gurny, R., and Arvinte, T. (2008) A high throughput protein formulation platform: a case study of salomon calcitonin. Pharm. Res., 26 (1), 118-128.
98. Peters, B.J.M., Capelle, M.A.H., Arvinte, T., and van de Garde, E.M.W. (2012) Validation of an automated method for compounding monoclonal antibody patient doses. MAbs, 5 (1), 162-170.
99. Capelle, M.A.H., Gurny, R., and Arvinte, T. (2007) High throughput screening of protein formulation stability:practical consideration. Eur. J. Pharm. Biopharm., 65, 131-148.
100. Wang, W. (1999) Instability, stabilisation and formulation of liquid protein pharmaceuticals. Int. J. Pharm., 185 (2), 129-188.
101. Ahern, T.J., Manning, M. C. (1992) Stability of protein pharmaceutical. Part A, Chemical and physical pathways of protein degradation. Plenum Press, New York.
102. Wang, W. (2000) Lyophilisation and development of solid protein pharmaceuticals. Int. J. Pharm., 203 (1-2), 1-60.
103. Matejtschuk, P. (2007) Lyophilization of proteins. Methods Mol. Biol., 368, 59-72.
104. Franks, F. and Auffret, T. (2008) Freeze-drying of Pharmaceuticals and Biopharmaceuticals, RSC Publishing, London.
105. Matejtschuk, P., Andersen, M., and Phillips, P. (2004) in Freeze Drying/Lyophilization of Pharmaceutical and Biological Products, 2nd edn (eds L. Rey and J.C. May), Marcel Dekker, New York, pp. 385-424.
106. Jennings, T.A. (1999) Lyophilisation:Introduction and Basic Principles, Interpharm Press, Englewood. CO.
107. Matejtschuk, P., Mailik, K., Duru, C., Bristow, A. (2009) Freeze drying of biologicals:Process development to ensure biostability lyophilisation. American pharmaceutical review, 12 (2), 18-26.
108. Schersch, K., Betz, O., Garidel, P., Muehlau, S., Bassarab, S., and Winter, G. (2012) Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins, part 2: stability during storage at elevated temperatures. J. Pharm. Sci., 101 (7), 2288-2306.
109. Shire, S.J., Shahrokh, Z., and Liu, J. (2004) Challenges in the development of high protein concentration formulations. J. Pharm. Sci., 93 (6), 1390-1402.
110. Zlokarnik, M. (2002) Scale-Up in Chemical Engineering. Weinheim:Wiley VCH.
111. Hass, V.C. and Pförtner, R. (2011) Praxis der Bioprozesstechnik, 2. Auflage, Spektrum Akademischer Verlag.
112. Marks, D.M. (2003) Equipment design considerations for large scale cell culture. Cytotechnology, 42, 21-33.
113. Shulka, A.A., Hubbard, B., Tressel, T., Guhan, S., and Low, D. (2007) Downstream processing of monoclonal antibodies - Application of platform approaches. J. Chromatogr. B, 848, 28-39.
114. Sofer, G. and Hagel, L. (1997) Handbook of Process Chromatography - A Guide to Optimization, Scale-UP and Validation, Academic Press, New York, pp. 27-113.
115. Rathore, A.S. and Velayudhan, A. (2003) Overview of Scale-Up in Preparative Chromatography, Chromatographic Science Series, Marcel Dekker, Inc.
116. Kelley, B. (2007) Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnology progress, 23, 995-1008.
117. Shulka, A.A. and Thömmes, J. (2010) Recent advances in large-scale production of monoclonal antibodies and related of protein. Trends Biotechnol., 28 (5), 253-261.
118. Zydney, A.L., Harinarayan, C., and van Reis, R. (2009) Modeling electrostatic exclusion effects during ion exchange chromatography of monoclonal antibodies. Biotechnol. Bioeng., 102 (4), 1131-1140.
119. Sommerfeld, S. and Strube, J. (2005) Challenges in biotechnology production-generic processes and process optimization for monoclonal antibodies. Chem. Eng. Process., 44, 1123-1137.
120. Przybycien, T.M., Pujar, N.S. and Steele, L.M. (2004) Alternative bioseparation operations: life beyond packed-bed chromatography. Current Opinion in biotechnology, 14, 469-478.
121. Myers, J. (2000) Economic considerations in the development of downstream steps for large scale commercial biopharmaceutical processes. IBC: Production and Economics of Biopharmaceuticals, 11, 13-15.
122. Werner, R. (2004) Economic aspects of commercial manufacture of biopharmaceuticals. J. Biotechnol., 112, 171-182.
123. Farid, S.S. (2009) Economic drivers and trade-offs in antibody purification processes. The future of therapeutic MABs lies in the development of economically feasible downstream processes. BioPharm International Supplements.
124. Rawlings, B. and Pora, H. (2009) Environmental impact of single-use and reusable bioprocess systems. BioProcess Int., 7, 18-26
125. Sinclair, A., Leveen, L., Monge, M., Lim, J., and Cox, S. (2008) The Environmental impact of disposable technologies. BioPharm Int. com., 11.
126. Pais-Chanfrau, J.M., Zorrilla, K. and Chico E. 2009 The impact of disposables on project economics in a new antibody plant: A case study compares capital costs, operation expenses, and net present value for a new MAb plant. BioPharm International, 22 (12).
127. Zimmermann, H.F. and Hentschel, N. (2011) Proposal on how to conduct a biopharmaceutical process Failure Mode and Effect Analysis (FMEA) as a risk assessment tool. PDA J. Pharm. Sci. Technol., 65 (5), 506-512.
128. Seely, J.E. and Seely, R. (2003) A rational, step-wise approach to process characterization. BioPharm Int., 16, 24-34.
129. Harris, R.J., Kabakoff, B., Macchi, F.D., Shen, F.J., Kwong, M., Andya, J.D., Shire, S.J., Bjork, N., Totpal, K., and Chen, A.B. (2001) Identification of multiple sources of charge heterogeneity in a recombinant antibody. J. Chromatogr. B, 752, 233-245.
130. CPMP/3097/02 (2003) Note for Guidance on Comparability of Medicinal Products containing Biotechnology-derived Proteins as Drug Substance - Non Clinical and Clinical Issues, www.emea.eu.int/index/indexh1.htm
131. Mechref, Y. and Novotny, M.V. (2002) Structural Investigations of glycoconjugates at high sensitivity. Chem. Rev., 102, 321-369.
132. Perczel, A., Hollósi, M., Tusnády, G., and Fasman, G.D. (1991) Convex constraint analysis: a natural deconvolution circular dichroism curves of proteins. Protein Eng., 4, 669-679.
133. Remmele, R.L. Jr., and Gombotz, W.R. (2000) Differential scanning calorimetry:a practical tool for elucidating stability in liquid pharmaceuticals. Biopharm, 13, 36-46.
134. Van der Weert, M., Haris, P.I., Hennink, W.E., and Crommelin, D.J.A. (2001) Fourier transform infrared spectrometric analysis of protein conformation:effect of sampling method and stress factors. Anal. Biochem., 297, 160-169.
135. Fersht, A.R. and Daggett, V. (2002) Protein folding and unfolding at atomic resolution. Cell, 108, 573-582.
136. Eckerskorn, C., Strupat, K., Karas, M., Hillenkamp, F., and Lottspeich, F. (1992) Mass spectrometric analysis of blotted proteins after gel-electrophoretic separation by matrix-assisted laser desorption ionization mass spectrometry. Electrophoresis, 13, 664-665.
137. Patterson, S.D. and Aebersold, R. (1995) Mass spectrometric approaches for the identification of gel-separated proteins. Electrophoresis, 16, 1791-1814.
138. Gianazza, E. (1995) Isoelectric focusing as a tool for the investigation of post-translational processing and chemical modifications of proteins. J. Chromatogr. A, 705, 67-87.
139. Good, D.L. (2004) Capillary electrophoresis of proteins in a quality control environment, in Capillary Electrophoresis of Proteins and Peptides, Methods in Molecular Biology, vol. 276, Humana Press Inc., Totowa, New Jersey.
140. Perkins, M., Theiler, R., Lunte, S., and Jeschke, M. (2000) Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm. Res., 17, 1110-1117.
141. Nguyen, D.N. et al. (1995) Protein mass spectrometry: applications to analytical biotechnology. J. Chromatogr. A, 705, 21-45.
142. Gorman, J.J., Wallis, T.P., and Pitt, J.J. (2002) Protein disulfide bond determination by mass spectrometry. Mass Spectrom. Rev., 21, 183-216.
143. Andersson, C. et al. (1996) Isolation and characterization of trisulfide variant of recombinant human growth hormone formed during expression in Escherichia coli. Int. J. Pept. Protein Res., 47, 311-321.
144. Stephenson, R.C. and Clark, S. (1989) Succinimide formation from aspartyl and asparaginyl peptides as a model for spontaneous degradation of proteins. J. Biol. Chem., 264, 6164-6170.
145. Zhang, W., Czupryn, J.M., Boyle, P.T. Jr., and Amari, J. (2002) Characterization of asparagine deamidation and aspartate isomerization in recombinant human interleukin-11. Pharm. Res., 19 (8), 1223-1231.
146. Teshima, G., Stults, J.T., Ling, V., Canova-Davis, E. (1991) Isolation and characterization of a succinimide variant of methionyl human growth hormone. J. Biol. Chem., 266 (21), 13544-13547.
147. Harris, R.J. (1995) Processing of Cterminal lysine and arginine residues of proteins isolated from mammalian cell culture. J. Chromatogr. A, 705, 129-134.
148. Prigge, S.T. (1997) Amidation of bioactive peptides: the structure of peptidylglycine-hydroxylating monooxygenase. Science, 278, 1300-1305.
149. Wang, L., Amphlett, G., Blättler, W.A., Lambert, J.M., and Zhang, W. (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Science, 14, 2436-2446.
150. Laue, T.M. and Stafford, W.F. (1999) Modern application of analytical ultracentrifugation. Annu. Rev. Biophys. Biomol. Struct., 28, 75-100.
151. Schimpf, M.E., Caldwell, K.D., and Giddings, J.C. (eds) (2000) Field-Flow Fractionation Handbook, Wiley-Interscience, New York.
152. Liu, T. and Chu, B. (2002) in Encyclopedia of Surface and Colloid Science (ed. P. Somasundran), Marcel Dekker, New York, pp. 3023-3043.
153. Andya, J.D., Hsu, C.C., and Shire, S.J. (2003) Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci., 5, 1-11.
154. Wright, A. and Morrison, S.L. (1998) Effect of C2-associated carbohydrate structure on IgG effector function:studies with chimeric mouse-human IGG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J. Immunol., 160, 3393-3402.
155. Jefferis, R. (2001) Glycosylation of human IgG antibodies: relevance to therapeutic applications. Biopharm, 14, 19-26.
156. Shields, R.L., Lai, J., Keck, R., O'Connell, L.Y., Hong, K., Meng, Y.G., Weikert, S.H., and Presta, L.G. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem., 277, 26733-26740.
157. Stockert, R.J. (1995) The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev., 75, 591-609.
158. Galili, U. (1992) The natural anti-Gal antibody: evolution and function. Immunology, 55, 355-373.
159. WHO Expert Committee on Biological Standardization (1997) Highlights of the 46th Meeting, October 1996. WHO Epidemiological Record, 72 (20), 143-145; www.who.int/docstore/wer/pdf/1997/wer7220.pdf.